Literature DB >> 16580635

Enhanced phagocytosis of CD47-deficient red blood cells by splenic macrophages requires SHPS-1.

Tomomi Ishikawa-Sekigami1, Yoriaki Kaneko, Yasuyuki Saito, Yoji Murata, Hideki Okazawa, Hiroshi Ohnishi, Per-Arne Oldenborg, Yoshihisa Nojima, Takashi Matozaki.   

Abstract

The interaction of CD47 on red blood cells (RBCs) with SHPS-1 on macrophages is implicated to prevent the phagocytosis of the former cells by the latter cells. Indeed, the rate of clearance of transfused CD47-deficient (CD47(-/-)) RBCs from the bloodstream of wild-type mice was markedly increased compared with wild-type RBCs. Conversely, the rate of clearance of transfused wild-type RBCs was markedly increased in mice that expressed a mutant form of SHPS-1 lacking most of the cytoplasmic region of the protein. However, we here found that the clearance of CD47(-/-) RBCs in SHPS-1 mutant mice was minimal. In addition, the phagocytosis of CD47(-/-) RBCs by splenic macrophages from SHPS-1 mutant mice was markedly reduced compared with wild-type macrophages. These results thus suggest an additional role for CD47 on RBCs in the negative regulation of phagocytosis by macrophages and in determination of the life span of circulating RBCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580635     DOI: 10.1016/j.bbrc.2006.03.094

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Reply to "On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer".

Authors:  Yuhua Wang; Zhenghong Xu; Leaf Huang
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

2.  Physiologically aged red blood cells undergo erythrophagocytosis in vivo but not in vitro.

Authors:  Yehonatan Gottlieb; Orit Topaz; Lyora A Cohen; Liat David Yakov; Tom Haber; Abigail Morgenstern; Avital Weiss; Karen Chait Berman; Eitan Fibach; Esther G Meyron-Holtz
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

3.  MiR-155 enhances phagocytic activity of β-thalassemia/HbE monocytes via targeting of BACH1.

Authors:  Kanitta Srinoun; Chamnong Nopparatana; Malai Wongchanchailert; Suthat Fucharoen
Journal:  Int J Hematol       Date:  2017-07-06       Impact factor: 2.490

Review 4.  Emerging immunotherapeutic strategies for the treatment of breast cancer.

Authors:  Laura A Huppert; Veronica Mariotti; A Jo Chien; Hatem H Soliman
Journal:  Breast Cancer Res Treat       Date:  2021-10-30       Impact factor: 4.872

Review 5.  Targeting CD47 as a Novel Immunotherapy for Breast Cancer.

Authors:  Can Chen; Runlu Wang; Xi Chen; Yulong Hou; Jingting Jiang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

6.  Endothelial CD47 interaction with SIRPgamma is required for human T-cell transendothelial migration under shear flow conditions in vitro.

Authors:  Michael Stefanidakis; Gail Newton; Winston Y Lee; Charles A Parkos; Francis W Luscinskas
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

7.  CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.

Authors:  Oliver Jay Broom; Yuan Zhang; Per-Arne Oldenborg; Ramin Massoumi; Anita Sjölander
Journal:  PLoS One       Date:  2009-07-28       Impact factor: 3.240

Review 8.  Role of CD47 in Hematological Malignancies.

Authors:  Entsar Eladl; Rosemarie Tremblay-LeMay; Nasrin Rastgoo; Rumina Musani; Wenming Chen; Aijun Liu; Hong Chang
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

Review 9.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.

Authors:  Wenting Zhang; Qinghua Huang; Weiwei Xiao; Yue Zhao; Jiang Pi; Huan Xu; Hongxia Zhao; Junfa Xu; Colin E Evans; Hua Jin
Journal:  Front Immunol       Date:  2020-01-28       Impact factor: 7.561

Review 10.  CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer.

Authors:  Rodrigo Catalán; Mario Orozco-Morales; Norma Y Hernández-Pedro; Alberto Guijosa; Ana L Colín-González; Federico Ávila-Moreno; Oscar Arrieta
Journal:  J Immunol Res       Date:  2020-09-19       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.